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Abstract
Background: Pro-inflammatory cytokines possess osteoclastogenic or anti-osteoclastogenic activities. They
influence osteoclasts directly or via the receptor activator of nuclear factor B (RANK), RANK ligand (RANKL) and
osteoprotegerin (OPG) system. Recent evidence suggests that inflammation may play a role in osteoporosis (OP)
and osteoarthritis (OA). We aimed therefore to determine whether there is a difference between both groups: first,
in the expression of the osteoclastogenic and anti-osteoclastogenic cytokines, second, in correlation of these
cytokines with bone mineral density (BMD) and levels of bone turnover markers (BTM) and third, in correlation
between the expression of these cytokines and osteoclast specific genes and RANK/RANKL/OPG genes.
Methods: Human bone samples from 54 age and sex matched patients with OP or OA were collected during hip
arthroplasty surgery. The expression of 25 genes encoding pro-inflammatory cytokines, their receptors, osteoclast
specific genes and RANK/RANKL/OPG genes was measured using quantitative real-time PCR. Total hip, femoral
neck and lumbar spine BMD and BTM in blood samples were measured. The comparison between OP and OA was
assessed using Student’s t-test or Mann-Whitney U test and correlations between gene expression, BMD and BTM
were determined using nonparametric correlation.
Results: The results demonstrated a higher expression of interleukin (IL)-6 and IL-1a in OP, and interferon (IFN)-g in
OA (p < 0.0005). Negative correlations of total hip BMD with tumor necrosis factor-a (TNF-a) in OA and with
RANKL/RANK in OP were found (p < 0.05). Significant correlations with BTM were shown for IL-1a and IFN-g in OP
(rho = 0.608 and -0.634) and for TNF-a, IL-6 and transforming growth factor-b1 (TGF-b1) in OA (rho = 0.591, -0.521
and 0.636). Results showed OP specific negative correlations (IFN-g with ITGB3, IFN-b1 with CTSK, tartrate resistant
acid phosphatase (TRAP), CALCR, RANK, RANKL, IL-1a with CTSK, OPG, IL-17A with CALCR) and positive (TGF-b1w i t h
CTSK, TRAP, RANK), and OA specific negative (IL-1a with osteoclast associated immunoglobulin-like receptor
(OSCAR), TNF-a with RANK, RANKL, OPG) and positive (IL-6 with RANK, RANKL, OPG) correlations.
Conclusions: Our results demonstrate that the relationship between osteoclastogenic and anti-osteoclastogenic
pro-inflammatory cytokines differs in human OP and OA bone and could present an important factor for
characteristics of OP and OA bone phenotypes.
Keywords: Interleukins, Interferons, TNF-α, TGF-β1, β3 integrin, Cathepsin K, OSCAR
* Correspondence: janja.zupan@ffa.uni-lj.si
1University of Ljubljana, Faculty of Pharmacy, Department of Clinical
Biochemistry, Askerceva cesta 7, SI-1000 Ljubljana, Slovenia
Full list of author information is available at the end of the article
Zupan et al. Journal of Biomedical Science 2012, 19:28
http://www.jbiomedsci.com/content/19/1/28
© 2012 Zupan et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Osteoclasts are influenced by a variety of pro-inflamma-
tory osteoclastogenic and anti-osteoclastogenic cytokines
that can either stimulate or suppress their activity [1]. This
regulation of osteoclasts becomes particularly important in
the pathological activation of the immune system, when
pro-inflammatory cytokines are produced extensively by
activated T cells [2]. As the immune system is also trig-
gered during estrogen deficiency or inflammation, both
osteoporosis (OP) and osteoarthritis (OA) are being
recently considered as inflammation driven bone disorders
[3,4]. Increased levels of IL-1, TNF-a and IL-6 after the
menopause have been associated with OP [5-8] and higher
incidence of non-traumatic fractures was associated with
higher levels of serum IL-6 [9]. Furthermore, serum IL-6
accounted for up to 34% of the total variance of change in
bone mineral density (BMD) after the menopause [10].
Blockade of TNF and IL-1 reduced bone resorption in
postmenopausal OP women [11].
Anti-osteoclastogenic cytokines such as IFN-g and
IFN-b have been shown in vitro to strongly suppress
osteoclastogenesis by inhibiting receptor activator of
nuclear factor B (RANK) signalling [12,13]. However,
under conditions of inflammation and estrogen defi-
ciency, this effect of IFN-g could be overpowered by T
cell secretion of RANKL and TNF-a, resulting in net
bone loss [2,14]. Transforming growth factor b1( T G F -
b1) cannot be classified as a pro-inflammatory cytokine,
however its role in maintaining a balance, by mediating
both inhibition and stimulation of bone resorption and
formation, could be deregulated by the pro-inflamma-
tory cytokines released in pathological conditions of
bone [15].
Pro-inflammatory cytokines, such as IL-1a,T N F - a
and IL-17 exhibit osteoclastogenic properties [16,17]
with many synergistic and also antagonizing interactions
b e t w e e nt h e m[ 1 8 - 2 1 ]a n ds o m eo ft h e m ,s u c ha sI L - 6 ,
may produce both stimulatinga n ds u p p r e s s i n ga c t i o n s
on osteoclasts [17,22,23].
In vitro studies have shown that these cytokines can
influence osteoclasts directly via their specific receptors
located on osteoclasts or via modulation of the RANK/
RANK ligand (RANKL)/osteoprotegerin (OPG) system
[24-26]. IL-1a,I L - 6a n dT N F - a can act on osteoclasts
directly or by the RANK/RANKL/OPG pathway
[16,22,27]. Regardless of the pathway, the activation of
osteoclasts leads to the expression of the osteoclast spe-
cific genes CALCR, ITGB3, OSCAR, CTSK and ACP5
that encode calcitonin receptor, b3 integrin, osteoclast
associated immunoglobulin-like receptor (OSCAR),
cathepsin K and tartrate resistant acid phosphatase
(TRAP) respectively, all of which are involved in differ-
entiation, activation and survival of osteoclasts [28].
These data, obtained mainly from in vitro studies and
experimental animal models, indicate complex crosstalk
between the pro-inflammatory cytokines, and strongly
suggest that the exact outcome of the specific cytokine
must be evaluated in pathological conditions of the
bone microenvironment. One of the first studies on
human bone biopsies, performed by Ralston in 1994,
demonstrated that the expression of IL-1a,I L - 1 b,T N F -
a and IL-6 is more frequent in women with OP frac-
tures than in normal postmenopausal women [29].
Recently, D’Amelio et al. found up regulation of expres-
sion of RANKL and OPG genes in OP, while TGF-b
was highly expressed in OA women [30]. To the best of
our knowledge the expression of anti-osteoclastogenic
cytokines, such as IFN-g and IFN-b, has not been quan-
tified in human OP or OA bone tissue so far. Due to
ethical reasons, normal human bone tissue is difficult to
obtain and studies utilizing normal human iliac crest
bone [29] and intertrochanteric bone obtained from
cadavers at autopsy [31,32] are limited.
OP and OA are two contrasting bone phenotypes in
terms of BMD [33], and both have only recently been
considered as inflammatory bone disorders [3,4] in
which osteoclastogenic and anti-osteoclastogenic cyto-
kines might play important roles.
Given these observations the aim of our study was to
investigate, whether there is a difference between OP
and OA: first, in the expression of the osteoclastogenic
and anti-osteoclastogenic cytokines, second, in correla-
tion of these cytokines with BMD and levels of bone
turnover markers (BTM) and third, in correlation of
these cytokines with osteoclast specific genes and
RANK/RANKL/OPG genes.
Therefore, the gene expression of 15 pro-inflammatory
cytokines including their receptors, TGF-b1a n di t s
receptor, 3 genes of the RANK/RANKL/OPG system
and 5 osteoclast specific genes, in human OP and OA
bone tissue, was examined. IFN-g and IFN-b have been
quantified for the first time in human OP and OA bone
tissue.
Methods
Human bone tissue samples
Gene expression profiles were determined in bone sam-
ples from fifty four (54) patients undergoing hemi-
arthroplasty or total hip arthroplasty because of low-
energy femoral neck fracture (23 OP patients) or pri-
mary hip OA (31 OA patients). Patients were included
in the study in a consecutive manner over a period of
1.5 years as they were directed to arthroplasty at the
Department of Traumatology in the General Hospital
Celje because of diagnosis of OP or OA. OP was diag-
nosed by radiologically confirmed low-energy femoral
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clinical and radiographic criteria according to the Harris
hip score [34]. All OP patients were submitted to
arthroplasty within 24 h following femoral neck fracture.
Bone tissue samples (approximately 1 cm
3)w e r ec o l -
lected during surgical procedures of femoral osteotomy
from the trabecular bone at the metaphyseal cutting
plane. Bone samples were immediately frozen in liquid
nitrogen and stored at -80°C until RNA extraction. The
exclusion criteria for enrollment of OP and OA patients,
verified by the questionnaire, laboratory results and
interview, included the following: secondary OP or OA,
liver and kidney diseases, endocrinological disorders and
medical anamnesis on receiving medications with
known influence on bone metabolism. The study was
approved by the ethical committee of Republic of Slove-
nia and all patients gave written informed consent.
Bone mineral density measurement
BMD at the contralateral hip, lumbar spine (L2-L4) and
femoral neck was measured by dual-energy X-ray
absorptiometry (Hologic QDR 1000, Hologic, Inc. Bed-
ford). The measurement of BMD in OA patients was
performed pre-operatively and in OP patients immedi-
ately post-operatively.
Biochemical markers of bone turnover
Biochemical BTM were measured in a subset of 28
patients (12 OP and 16 OA) within 24 days after sur-
gery. Blood samples were collected between 8:00 a.m.
and 10:00 a.m. after an overnight fast. Serum C-terminal
crosslinking telopeptides of type I collagen (CTX),
serum free soluble RANKL, cathepsin K and OPG were
measured by enzyme immunoassay (Serum CrossLaps
ELISA, Nordic Bioscience Diagnostics A/S, Herlev, Den-
mark; sRANKL ELISA, Cathepsin K ELISA and Osteo-
protegerin ELISA, Biomedica, Vienna, Austria) with an
inter-assay coefficient of variation (CV) below 10%, 6%,
8% and 8%, respectively. Osteocalcin (OC) in hepari-
nized plasma was measured by a solidphase, two-site
chemiluminescent enzyme-labelled immunometric assay
(Immulite Osteocalcin, Diagnostic Product Corporation,
Los Angeles, CA, USA).
Quantitative real-time polymerase chain reaction
Total RNA was extracted from human bone samples
and complementary DNA (cDNA) synthesized according
to our previously described procedure [35] and stored at
-80°C until measurement of gene expression.
Predesigned and validated gene-specific TaqMan Gene
Expression Assays (Applied Biosystems, Foster, CA,
USA) for RANK (TNFRSF11A), IFN-g (IFNG), IL1A,I L -
1a receptor type I (IL1R1), IL-6 (IL6), TNF-a receptor
(TNFRSF1A)a n dOSCAR genes (Hs00921374_m1,
Hs99999041_m1, Hs00899848_m1, Hs00168392_m1,
Hs00174131_m1, Hs01042313_m1 and Hs01100185,
respectively) were used according to the manufacturer’s
protocol. For the remaining genes, oligonucleotides
(Sigma Aldrich Chemie Gmbh, Munich, Germany) for
mRNA encoding IFN-g receptor (IFNGR1), IFN-b
(IFNB1), both chains of IFN-b receptor (IFNAR1 and
IFNAR2), IL-1a receptor type II (IL1R2), IL-6 receptor
(IL6R), IL-17A (IL17A), two IL-17A receptors A and C
(IL17RA and IL17RC), TNF-a (TNF), TGF-b1( TGFB1),
TGF-b1 receptor TbR1 (TGFBR1), calcitonin receptor
(CALCR)a n db3 integrin (ITGB3)w e r ed e s i g n e du s i n g
Primer-BLAST (NCBI). Real time quantification was
carried out on LightCycler 480 (Roche Diagnostics Ltd,
Rotkreuz, Switzerland) using 5× HOT FIREPol Eva-
Green qPCR Mix Plus for oligonucleotides and 5× HOT
FIREPol Probe qPCR Mix Plus (Solis BioDyne, Tartu,
Estonia) for TaqMan assays. All samples were quantified
in triplicate. Dilution series of cDNA were prepared to
create a relative standard curve with each run and abso-
lute quantification of the data was performed using the
second derivative maximum method (LightCycler 480,
Software Version 1.5, Roche Diagnostics Ltd, Rotkreuz,
Switzerland). All data were normalized to the geometric
mean of two internal housekeeping genes, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH)a n dr i b o s o -
mal protein, large, P0 (RPLP0). Data on TNFSF11,
TNFRSF11B, ACP5 and CTSK expression were taken
from our previous study on the same group of patients
[35] and the appropriate correction factor, according to
expression of two housekeeping genes, was applied.
Statistical analysis
Variables were tested for normality of distribution using
the Shaphiro-Wilk test. For variables such as age, sex,
body mass index and BMD, that have met the normality
assumption, Student’s t-test was used for comparison
between the two groups of patients. Because of the non-
parametric distribution of the BTM levels and mRNA
data, Mann-Whitney U test was used for comparison
between the two tissue groups, and Spearman rho corre-
lation analysis for estimating the relationship between
the gene expression data, BMD and BTM, and within
the mRNA data, respectively. Results with a p value of
0.05 or less were considered statistically significant. All
data analyses were performed using PASW software,
version 18 (IBM, Chicago, IL, USA).
Results
Study population
The study population consisted of age and sex matched
patients with femoral neck fracture due to low-energy
trauma (OP) and patients witha r t h r o p l a s t ic surgery of
the hip (OA). The two groups differed in body mass
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and lumbar spine, these values being significantly lower
in OP than in OA. Cathepsin K and OPG serum levels
were significantly higher in OP (Table 1).
Gene expression measurement
The expression of 25 genes encoding 15 pro-inflamma-
tory cytokines and their receptors (I L 1 A ,I L 6 ,I F N G ,
IFNB1, IL17A, TNF, IL1R1, IL1R2, IL6R, IFNG1,
IFNAR1, IFNAR2, IL17RA, IL17RC, TNFRSF1A), TGF-
b1 and its receptor (TGFB, TGFBR1), 3 genes of the
RANK/RANKL/OPG system (TNFRSF11A, TNFSF11,
TNFRSF11B) and 5 osteoclast specific genes (ITGB3,
OSCAR, CTSK, ACP5, CALCR) in human OP and OA
bone tissue was measured. All mRNA values were nor-
malized to the geometric mean of GAPDH and RPLP0
mRNA. Ligand to receptor mRNA levels for each of the
studied cytokine ligand receptor pairs were calculated
from normalized expression data and these ratios were
used further in our correlation analyses. Excluding Back-
ground, the name of the specific pro-inflammatory cyto-
kine is referred to the corresponding ligand receptor
mRNA ratio throughout the manuscript.
Difference in gene expression between OP and OA
The results of Mann-Whitney U tests showed no differ-
ences between males and females in the whole study
group or within OP or OA groups in the expression
levels of genes measured.
The expression of osteoclastogenic and of anti-
osteoclastogenic cytokines between OP and OA tissues
were compared using the Mann-Whitney U test. In
OP tissue, a significantly higher expression of ligand
to receptor mRNA levels for IL1A/IL1R1, IL1A/IL1R2
and IL6/IL6R were observed, while in OA tissue, there
was a significantly higher expression of IFN-g ligand
to receptor mRNA (Figure 1). Looking at the osteo-
clast specific genes, there was higher expression of
OSCAR and CALCR in OA, while higher expression of
ACP5 in OP was of limited statistical significance (p =
0.049). TNFRSF11A and TNFSF11 were both signifi-
cantly higher in OP, while their ratio did not reach
the level of significance. TNFRSF11B was similar
between both groups, while the ratio with RANKL
(TNFSF11/TNFRSFS11B) was significantly higher in
OP (Table 2).
Correlation of the pro-inflammatory cytokines with bone
mineral density
The correlation between cytokine ligand to receptor
mRNA levels and BMD was determined by nonpara-
metric analysis. In OP, significant negative association
with both, hip and femoral neck BMD was found for
RANKL/RANK (rho = -0.452 and -0.443, p < 0.05). In
OA, significant negative correlation was observed for
TNF/TNFRSF1A with hip BMD (rho = -0.390, p < 0.05),
while correlation with femoral neck BMD did not reach
the level of significance (rho = -0.355, p = 0.058).
Significant negative correlations of RANKL/OPG with
total hip and femoral neck BMD (p = -0.306 and -0.383,
p < 0.05) were found in the whole study group only.
Correlation of the pro-inflammatory cytokines with bone
turnover markers
The correlation between cytokine ligand to receptor
mRNA levels and BTM was determined by nonpara-
metric analysis. In OP, significant positive association
for IL1A/IL1R2 with serum RANKL and negative for
IFN-g ratio with serum cathepsin K have been found
(rho = 0.608 and -0.634, p < 0.05). In OA, significant
positive correlation was observed for TGF-b1r a t i ow i t h
serum OPG and TNF-a ratio with cathepsin K (rho =
0.636 and 0.591, p < 0.05), and a negative correlation of
IL-6 ratio with cathepsin K (rho = -0.521, p < 0.05).
Correlations between RANKL, RANKL/RANK, RANKL/
OPG mRNA and BTM were not significant for any of
the groups studied (p >0 . 0 5 ) ,w h i l eO P Gm R N A
showed significant negative correlation with serum OPG
in the OA group (rho = -0.518, p < 0.05).
Correlation of the pro-inflammatory cytokines with
osteoclast specific and RANK/RANKL/OPG genes
The correlation between cytokine ligand to receptor
mRNA levels and osteoclast specific genes, RANK,
RANKL and OPG gene mRNA was examined by non-
parametric analysis (Table 3).
Table 1 Anthropometric characteristics and serum levels
of bone turnover markers
Osteoporosis Osteoarthritis
Age (years) 74.1 ± 7.7 71.8 ± 4.2
Sex (women/men) 17/6 23/8
Body mass index (kg/m
2) 24.5 ± 2.3 28.3 ± 4.4**
Hip bone mineral density (g/cm
2) 0.726 ± 0.135 0.880 ± 0.140**
Femoral neck BMD (g/cm
2) 0.615 ± 0.098 0.757 ± 0.131**
Lumbar spine L2-L4 BMD (g/cm
2) 0.861 ± 0.184 0.994 ± 0.193*
CTX (pmol/l) 3078(1285;5391) 3547(2183;4967)
Osteocalcin (μg/l) 6.80(0.30;11.98) 7.90(1.03;17.03)
Cathepsin K (pmol/l) 12.0(10.0;22.1) 9.4(6.7;11.3)*
RANKL (pmol/l) 0.01(0.01;0.02) 0.01(0.01;0.06)
OPG (pmol/l) 5.86(4.52;7.47) 4.42(4.09;5.01)*
BMD bone mineral density. CTX C-terminal crosslinking telopeptides of type I
collagen. RANKL receptor activator of nuclear factor B ligand.
OPG osteoprotegerin.
Values are means ± standard deviation (with the exception of sex) and
medians(25th;75th quartile) for bone turnover markers.
Comparisons were assessed with Student’s t-test or Mann-Whitney U test, *p
< 0.05, **p < 0.001.
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correlation with ITGB3 and TGF-b1w i t hCTSK and
ACP5. Significant negative correlations were found for
the IL-6 with CTSK and CALCR, IL1A/IL1R1 ratio with
CTSK, and IL-17A with CALCR for ligand to receptor
ratios with both of its receptors IL-17RA and IL-17RC,
while IL17A/IL17RA also showed negative correlation
with CTSK. Significant negative correlation of both
IL1A/IL1R1 and IL1A/IL1R2 with OPG was found. Only
TGF-b1 showed significant positive correlation with
RANK. Negative correlations were demonstrated for IL-
17A ligand to receptor ratios, with both IL-17RA and
IL-17RC, and for IL-6 ratio with RANK.
Anti-osteoclastogenic cytokines in OP tissue showed a
significant negative correlation for IFN-g ligand to recep-
tor ratio (IFNG/IFNGR1) with ITGB3 and for IFN-b ratio
with CTSK, CALCR and ACP5. The latter observations
were found for both ligand to receptor mRNA ratios,
IFNB1/IFNAR1 and IFNB1/IFNAR2, as there are two pro-
tein chains of IFN-b receptor. A significant negative corre-
lation of both IFNB1/IFNAR1 and IFNB1/IFNAR2 with
RANK and RANKL gene expression was also found.
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Figure 1 Quantitative real-time PCR data of the pro-inflammatory cytokine mRNA levels in osteoporosis (OP) and osteoarthritis (OA).
Ligand to receptor ratios for each of the studied cytokine ligand receptor pairs were calculated from mRNA values normalized to geometric
mean of GAPDH and RPLP0 mRNA. Values are medians. Comparisons were assessed by the Mann-Whitney U test, *p values < 0.05 were
considered statistically significant.
Table 2 Data on mRNA levels of osteoclast specific genes and RANK/RANKL/OPG genes in OP and OA
Gene symbol Gene name OP (n = 23) OA (n = 31) OP/OA
a p value
b
Osteoclast specific genes
OSCAR Osteoclast associated immunoglobulin-like receptor 0.574(0.345;0.854) 1.002(0.732;1.339) 0.54 0.002*
ITGB3 b3 integrin 0.241(0.074;0.586) 0.285(0.143;0.994) 0.85 0.231
CTSK Cathepsin K 0.288(0.121;1.109) 0.263(0.136;0.555) 1.10 0.786
ACP5 Tartrate resistant acid phosphatase (TRAP) 0.270(.128;1.011) 0.147(0.073;0.259) 1.84 0.049*
CALCR Calcitonin receptor 0.223(0.138;0.644) 0.860(0.482;1.562) 0.26 < 0.0005**
RANK/RANKL/OPG genes
TNFRSF11A Receptor activator of nuclear factor B (RANK) 1.580(0.687;3.939) 0.573(0.355;1.038) 2.76 0.002*
TNFSF11 Receptor activator of nuclear factor B ligand (RANKL) 0.528(0.076;1.038) 0.091(0.027;0.253) 5.80 < 0.0005**
TNFRSF11B Osteoprotegerin (OPG) 0.699(0.410;0.914) 0.776(0.308;1.615) 0.90 0.681
TNFSF11/TNFRSF11A RANKL/RANK 0.241(0.083;0.928) 0.140(0.064;0.271) 1.72 0.076
TNFSF11/TNFRSF11B RANKL/OPG 0.448(0.295;1.601) 0.112(0.075;0.193) 4.00 < 0.0005**
Values are medians(25th;75th percentile). All mRNA values were normalized to the geometric mean of GAPDH and RPLP0 mRNA.
aGene expression ratio of medians in osteoporotic (OP) versus osteoarthritic (OA) patients.
bComparisons were assessed by the Mann-Whitney U test. *p < 0.05, **p < 0.001.
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Page 5 of 10Table 3 Correlation of the expression of the pro-inflammatory cytokines and osteoclasts’ specific genes and RANK/RANKL/OPG genes
Gene mRNA OSCAR b3 integrin Cathepsin K TRAP Calcitonin receptor RANK RANKL OPG
Ligand/Receptor mRNA ratio OP OA OP OA OP OA OP OA OP OA OP OA OP OA OP OA
IL6/IL6R -0.282 -0.215 0.587* -0.363* -0.451* 0.519** -0.329 0.319 -0.431* 0.656** -0.421 0.658** 0.083 0.619** -0.147 0.529**
IL1A/IL1R1 -0.181 -0.156 0.239 0.137 -0.508* -0.166 -0.350 0.021 -0.494* -0.434* -0.311 -0.301 -0.259 -0.258 -0.484* -0.296
IL1A/IL1R2 -0.021 -0.380* 0.100 -0.005 -0.103 0.325 0.015 0.348 -0.084 0.207 0.027 0.305 -0.066 0.337 -0.491* 0.271
TGFB1/TGFBR1 0.054 -0.198 0.112 0.256 0.473* -0.075 0.486* 0.048 0.302 -0.201 0.531* -0.051 0.263 -0.208 0.027 -0.033
IL17A/IL17RA 0.007 0.030 -0.116 0.167 -0.491* -0.081 -0.263 -0.084 -0.600** 0.087 -0.605** 0.002 -0.293 -0.009 0.068 0.021
IL17A/IL17RC -0.140 0.010 -0.358 -0.070 -0.390 -0.154 0.213 -0.004 -0.600* -0.095 -0.537* -0.096 -0.005 -0.027 0.213 -0.004
IFNG/IFNGR1 0.198 -0.181 -0.601** -0.062 0.119 0.205 -0.018 0.097 0.191 0.120 -0.070 0.207 -0.197 0.296 0.337 0.167
IFNB1/IFNAR1 0.224 0.006 0.095 0.188 -0.553** -0.283 -0.453* -0.290 -0.527** -0.038 -0.580** -0.202 -0.447* -0.186 0.002 -0.070
IFNB1/IFNAR2 0.313 -0.049 0.013 0.107 -0.510* -0.137 -0.430* -0.152 -0.463* 0.064 -0.517* -0.052 -0.456* -0.035 0.043 0.063
TNF/TNFRSF1A 0.329 0.292 -0.038 0.018 -0.428* -0.632** -0.429* -0.598** -0.414* -0.613** -0.362 -0.631** -0.356 -0.541** 0.192 -0.534**
OSCAR osteoclast associated immunoglobulin-like receptor. TRAP tartrate resistant acid phosphatase. RANK receptor activator of nuclear factor B. RANKL RANK ligand. OPG osteoprotegerin.
The numbers are Spearman’s rho coefficients for osteoporotic (OP) and osteoarthritic (OA) tissue. p values were obtained using nonparametric bivariate correlation analysis, *p < 0.05, **p < 0.01. Significant positive
correlations are underlined with bold line.
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0In OA tissue, interestingly, correlations directly oppo-
site to those in OP tissue were found for IL-6 ratio with
ITGB3, CTSK and CALCR. Furthermore, the ratio of IL-
1a to its receptor type II (IL1A/IL1R2)s h o w e dan e g a -
tive correlation with OSCAR. Strong negative correlation
of TNF-a ratio with RANK, RANKL and OPG, and an
opposite, positive correlation of IL-6 ratio with the same
genes, were found.
No significant correlations for IFN-g and IFN-b were
found with any of the osteoclast specific genes in OA.
In both tissues, IL1A/IL1R1 was significantly inversely
correlated with CALCR, while TNF-a ratio showed sig-
nificant negative correlations with CTSK, ACP5 and
CALCR.
Discussion
We have demonstrated that the relationship between
osteoclastogenic and anti-osteoclastogenic pro-inflam-
matory cytokines differs in human OP and OA bone.
The comparison of OP and OA showed higher expres-
sion of osteoclastogenic cytokines IL-6 and IL-1a in OP
and higher expression of IFN-g in OA. Negative associa-
tion with BMD has been found for RANKL in OP and
for TNF-a in OA. In OP, positive association of IL-1a
with serum RANKL and negative of IFN-g with serum
cathepsin K have been found, while in OA, positive cor-
relation of TGF-b1 with serum OPG and of TNF-a with
cathepsin K, and negative correlation of IL-6 with cathe-
psin K were observed. The correlations of IL-6 with
osteoclasts specific genes ITGB3, CTSK and CALCR
expression were directly opposite between OP and OA.
The negative correlations specific to OP were IL-1a
with CTSK and OPG, IL-17A with CALCR,I F N - g with
ITGB3,I F N - b with CTSK, ACP5, CALCR,R A N Ka n d
RANKL and positive correlations specific to OP were
TGF-b1 with RANK, TRAP and cathepsin K. The nega-
tive correlations specific for OA were IL-1a with
OSCAR and TNF-a w i t hR A N K ,R A N K L ,O P G ,a n d
positive OA specific IL-6 with RANK, RANKL and
OPG.
OP and OA are both age related skeletal disorders, in
which the involvement of pro-inflammatory cytokines,
due to pathological activation of the immune system,
was recently suggested [3,4]. As OP and OA are two
opposite bone phenotypes in terms of BMD [33], our
hypothesis was that the two types of tissue differ in the
relationship between osteoclastogenic and anti-osteo-
clastogenic pro-inflammatory cytokines and in the cor-
relation of these pro-inflammatory cytokines with BMD
and BTM. Bone samples were collected from OP and
OA patients with significantly different BMD at three
skeletal sites (Table 1). The results show higher expres-
sion of IL-6 and IL-1a in OP, while the expression of
IFN-g was higher in OA tissue. Although our results
were significant only for IL-1a,I L - 6a n dI F N - g,h i g h e r
expression of all osteoclastogenic cytokines studied,
except TNF-a was implied in OP, and higher expression
of the anti-osteoclastogenic cytokines IFN-g and IFN-b
in OA (Figure 1). The higher expression of genes encod-
ing bone resorption molecules TRAP, RANK and
RANKL and RANKL/OPG in OP tissue confirms the
adequacy of the system used in our study. In OA,
OSCAR and CALCR were significantly higher expressed
(Table 2). Interestingly, a previous study comparing OA
with controls from cadavers found no differences in
CALCR expression [32].
Our results show that the relationship between osteo-
clastogenic cytokines IL-6 and IL-1a and the anti-osteo-
clastogenic cytokine IFN-g is diametrically opposite in
OP and OA, corresponding to their bone phenotype. In
accordance with in vitro studies, higher level of the anti-
osteoclastogenic cytokine IFN-g in OA might contribute
to the suppressed osteoclast activity [13], while higher
levels of the osteoclastogenic cytokines IL-6 and IL-1a
in OP could suggest enhanced osteoclastogenesis, lead-
ing to increased bone loss [1,16,20,22]. Our results of
higher expression of IL-6 and IL-1a in OP and no dif-
ference in TNF-a expression are in accordance with
those of Ralston [29]. Furthermore, our results for IL-6
also coincide with those of Cauley et al. who showed
that high serum levels of IL-6 predict a higher incidence
of non-traumatic fractures. They found similar associa-
tion for TNF-a, while in our study TNF-a ratio showed
negative correlation with total hip BMD in OA [9].
Nevertheless, the negative correlations of RANKL/
RANK in OP and RANKL/OPG in the whole group
with total hip and femoral neck BMD found in our
study are in accordance with the well-established role of
the RANK/RANKL system in bone [24]. We have found
tissue specific correlation of the pro-inflammatory cyto-
kines gene expression and serum levels of BTM such as
cathepsin K, RANKL and OPG. In OP, positive associa-
tion of IL-1a with serum RANKL might indicate the
osteoclastogenic activity of IL-1a, while negative asso-
ciation of IFN-g with serum cathepsin K might indicate
anti-osteoclastogenic activity of IFN-g, previously con-
firmed in vitro in mice [36]. In OA, positive correlation
for TGF-b1 with serum OPG and a negative correlation
of IL-6 with cathepsin K, that could indicate the anti-
osteoclastogenic actions of these cytokines, resulting in
bone sparing effect in OA, were found. The latter obser-
vation for IL-6 is in accordance with the previously
observed dual role of IL-6 on osteoclasts [17,22,23].
Although previous reports have shown an inverse rela-
tionship between RANKL bone mRNA and serum levels
in OA males [37], our results of this correlation analysis
did not reach the level of significance. The reason is
most likely due to low statistical power as there were
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estingly, we observed significant negative correlation
between OPG mRNA and serum OPG in the OA group
although Findlay et al. have found the opposite
correlation.
Our results of non-significant higher expression of
TGF-b1 ligand gene TGFB1 in OA (p =0 . 0 5 3 ,d a t an o t
shown) and higher expression of RANKL/OPG in OP (p
< 0.0005) correspond to results of the recent D’Amelio
et al. study, that they have also verified on the protein
level [30]. To the best of our knowledge, the expression
of IFN-g and IFN-b has not been previously quantified
in human OP or OA bone tissue.
Moreover, we performed a correlation analysis of the
pro-inflammatory cytokines and TGF-b1 expression
with osteoclast specific and RANK/RANKL/OPG genes.
Again, the differences between OP and OA were found.
IL-6 showed positive correlation with b3 integrin expres-
sion in OP, while a negative link with the same gene has
been found in OA. Furthermore, negative correlation of
IL-6 expression with genes encoding RANK, cathepsin
K and calcitonin receptor in OP and the positive corre-
lation with the same genes in OA, have been found.
The results for IL-6 in OA are in accordance with the
previously observed opposing data on IL-6 activity on
osteoclasts [17,22,23]. Nevertheless, the 21-fold higher
expression of IL-6 in OP and its positive correlation
with b3 integrin expression could indicate its osteoclas-
togenic effect in OP. Furthermore, both IL-6 and IFN-g
have shown directly opposite correlation with b3 integ-
rin expression between OP and OA, and also reverse
correlation between them (rho = -0.463, p < 0.05, data
not shown) that was specific for OP.
Another osteoclastogenic cytokine in our study, IL-1a
has shown positive correlation with serum RANKL and
negative correlation with OPG gene expression in OP
that might indicate its osteoclastogenic pathway. The
negative association of IL-1a with cathepsin K gene
expression is contrary to the results of Kamolmatyakul
et al. in mice. Negative correlations of IL-1a with
OSCAR gene expression specific to OA could indicate
the dual role of IL-1a, similar to that of IL-6. Neverthe-
less, IL-1a showed almost 10-fold higher expression in
OP than in OA. Our results might suggest that IL-1a in
OP could act via suppression of the OPG, the decoy
receptor for RANKL, resulting in less inhibition of
RANKL, increased serum RANKL and enhanced osteo-
clast activity observed in OP. Additional studies are
needed to confirm this suggestion.
The differences between OP and OA were also found
for TGF-b1, a ubiquitous growth factor retaining a bal-
ance in coupling bone resorption and formation [15].
TGF-b1 showed positive correlation with cathepsin K,
TRAP and RANK gene expression in OP that could
suggests the involvement of TGF-b1 in enhanced osteo-
clastogenesis in OP. Similarly, Yan et al. showed that
TGF-b1 stimulates the expression of CALCR and RANK
in TRAP positive osteoclasts in isolated murine monocy-
tic cells [38]. On the other hand, TGF-b1 positive corre-
lation with serum OPG in OA indicates its opposite,
anti-osteoclastogenic effect in OA. Furthermore, our
results showed a negative correlation of TGF-b1w i t h
IFN-b in OP tissue (rho = -0.536, p < 0.05, data not
shown), that is in accordance with the mechanism pro-
posed by Lovibond et al., in which TGF-b1 stimulates
osteoclast formation via suppression of the anti-osteo-
clastogenic effect of IFN-b [19].
Looking at the anti-osteoclastogenic cytokines in our
study, OP specific negative correlations of IFN-g with b3
integrin and of IFN-b with genes encoding cathepsin K,
calcitonin receptor, TRAP, RANK and RANKL were
found, that are in accordance with the anti-osteoclasto-
genic effect of IFN-g and IFN-b,p r o v e din vitro [12,13].
These relationships were specific for OP, although we
would have expected such connections indicating the
bone sparing effect in OA. However, in our study, IFN-g
was 3-fold higher expressed in OA associated with high
bone mass. Previously, IFN-g has been shown to down
regulate cathepsin K expression in co-cultures of mouse
osteoclasts and stromal cells [36], while in our study,
negative correlation of IFN-g with b3 integrin gene was
found that has not been described before and should be
further examined. Taking together the results for IL-6
and IFN-g, i.e. their inverse relationship, their inverse
link to their common target b3 integrin gene, and their
inverse expression between OP and OA, we suggest that
the difference in relationship between osteoclastogenic
cytokine IL-6 and anti-osteoclastogenic cytokine IFN-g
could contribute to different osteoclast activity and thus
might present an important factor for the distinctive
bone phenotypes seen in OP and OA.
For the last two cytokines TNF-a and IL-17A no dif-
ference between OP and OA was observed, moreover
the negative correlations with osteoclast specific and
RANK/RANKL/OPG genes are contrary to the previous
reports on their osteoclastogenic activity [16,17,21,25].
Negative association of TNF-a with BMD, RANK,
RANKL and OPG gene expression and a positive with
serum cathepsin K (rho = 0.591, p < 0.05), might also
indicate the dual role of TNF-a on osteoclastogenesis.
However, further studies are needed.
To summarize, our results of 1) higher expression of
IL-6 and IL-1a in OP, OP specific negative correlation
of RANKL with BMD, positive of IL-1a with serum
RANKL and negative correlation of IFN-g with serum
cathepsin K, and a positive link of IL-6 with b3 integrin
expression and negative of IL-1a with OPG 2) TGF-b1
positive correlation with cathepsin K, TRAP and RANK
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with serum OPG in OA and 3) higher expression of
IFN-g in OA, IFN-g negative link to b3 integrin expres-
sion, and IFN-b negative correlation with cathepsin K,
calcitonin receptor, TRAP, RANK and RANKL gene
expression in OP, demonstrate the difference in the
relationship between osteoclastogenic and anti-osteo-
clastogenic pro-inflammatory cytokines in OP and OA
bone.
The limitations of the current study present a rela-
tively low number of patients with BTM and the lack of
further functional confirmation of the significant asso-
ciations found in our study. As blood samples in this
study were collected after surgery, it might be argued
there could have been influence of surgery or immobili-
zation on levels of BTM. To test this hypothesis, initial
comparison of BTM levels in blood samples collected
within 7 days after surgery with blood samples collected
within 8-24 days after surgery was performed, and the
results showed no influence of the time of blood speci-
men collection on the levels of BTM studied. Due to
difficulty in obtaining normal human bone tissue, no
controls such as cadaveric bone samples [31,32], were
included in our study. However, the augmentation of
the pro-inflammatory cytokin e si sc h a r a c t e r i s t i co ft h e
pathological conditions of bone, such as inflammatory,
age and hormone related bone disorders. The advantage
of our study is that we evaluated the human bone tissue
ex vivo as it is by comparing the steady-state of the pro-
inflammatory cytokine gene expression in bone tissue,
originating from bone and bone marrow cells, between
the two opposite bone phenotypes. To avoid possible
post-fracture response affecting the steady-state of gene
expression, samples were taken from intertrochanteric
region, located distal to the site of fracture. The signifi-
cant correlations found in our study suggest the path-
ways for further evaluation of the pro-inflammatory
cytokines in OP and OA.
Conclusions
In conclusion, we have found that the relationship
between osteoclastogenic and anti-osteoclastogenic pro-
inflammatory cytokines differs in human OP and OA
bone tissue, corresponding to their specific bone pheno-
types. Our data support the recent reports on the role
of inflammation in OP and OA, and provide new path-
ways for the further investigation on the role of the pro-
inflammatory cytokines in human OP and OA.
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